3 Pharma Stocks Too Cheap to Ignore -Breaking
A new COVID-19 variant (omnicron), is raising concerns around the world. We think it might be smart to grab shares of high quality pharmaceutical stocks GlaxoSmithKline and Teva Pharmaceutical (TEVA), as they appear undervalued at current price levels. The stocks have an overall score of either A (Strong Buy), B (Buy), and A for Value in our POWR Ratings. Continue reading. Pharma stocks remain at the forefront, with new concerns about the new omicron-COVID-19 variant. On November 21, 2021, Dr. Anthony Fauci warned that time was running short to prevent a “dangerous” resurgence of COVID-19 infections during the upcoming holiday season. His statements are deemed to have piqued investor interest in the pharma sector, as evidenced by the iShares U.S. Pharmaceuticals ETF’s (IHE) 2.5% returns over the past month.
The pharmaceuticals industry is also expected to expand due to the rise in chronic diseases. Markets and Markets reports that the market for pharmaceutical drug delivery is growing at 5.9% annually, will show that it could reach $2.21 Trillion by 2026.
Therefore, we think it could be wise to add fundamentally sound yet undervalued pharmaceutical stocks GlaxoSmithKline plc (GSK), Teva Pharmaceutical Industries Limited (NYSE:), and Eagle Pharmaceuticals, Inc. (EGRX) to one’s portfolio now. Our POWR Ratings system gives these stocks an A or B grade. These stocks also hold an A rating for value.
Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.